Regeneron Pharmaceuticals cash flow from operating activities for the twelve months ending March 31, 2025 was $10.490B, a 12.59% decline year-over-year.
Regeneron Pharmaceuticals annual cash flow from operating activities for 2024 was $4.421B, a 3.78% decline from 2023.
Regeneron Pharmaceuticals annual cash flow from operating activities for 2023 was $4.594B, a 8.39% decline from 2022.
Regeneron Pharmaceuticals annual cash flow from operating activities for 2022 was $5.015B, a 29.18% decline from 2021.
Regeneron Pharmaceuticals Cash Flow from Operating Activities 2010-2025 | REGN